Gilead's Tybost gains EU nod, but commercial potential limited
This article was originally published in Scrip
Executive Summary
Gilead Sciences has been given the go-ahead by the European Commission to market its HIV boosting agent Tybost (cobicistat), but its chances of success as a standalone agent are slim and most of its potential lies in combination products.